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Summary Background Trifluridine, a thymidine-based che-
motherapeutic, has limited bioavailability after clinical admin-
istration as it is rapidly degraded via thymidine phosphory-
lase. An oral combination tablet combines trifluridine with a
potent thymidine phosphorylase inhibitor, tipiracil hydrochlo-
ride. This study’s objective was to evaluate whether
trifluridine/tipiracil (TAS-102) administration increases
trifluridine exposure vs trifluridine alone. Methods This
open-label pharmacokinetic study randomly assigned patients
with advanced solid tumors into two groups. On the morning
of day 1, one group received a single 35 mg/m2 dose of
trifluridine/tipiracil and the other group received a single 35-
mg/m2 dose of trifluridine. Both groups received trifluridine/
tipiracil 35 mg/m2 on the evening of day 1, then twice daily on
days 2–5 and 8–12 in a 28-day cycle. Results Twenty patients
received an initial one-time dose of trifluridine alone and 19
other patients received an initial dose of trifluridine/tipiracil.
Trifluridine area under the curve (AUC0-last) and maximum
observed plasma concentrations (Cmax) were approximately
37- and 22-fold higher, respectively, with trifluridine/tipiracil
vs trifluridine alone. Plasma concentrations of the major me-
tabolite of trifluridine were lower following the administration
of trifluridine/tipiracil vs trifluridine alone. Conclusion
Tipiracil administered in combination with trifluridine signif-
icantly increased exposure to trifluridine compared with
trifluridine alone.
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Introduction
Fluoropyrimidines have been widely used for decades for the
treatment of multiple neoplasms [1]. In the early 1960s, a
potent fluoropyrimidine, trifluridine, was developed [2].
Trifluridine is rapidly degraded to an inactive metabolite, 5-
trifluoromethyl-2,4(1H,3H)-pyrimidinedione (FTY), by thy-
midine phosphorylase, an enzyme found in the gastrointesti-
nal tract, liver, and tumor tissue [3, 4]. A consequence of
trifluridine’s rapid degradation by thymidine phosphorylase
is that trifluridine has poor bioavailability [5]. While intrave-
nous trifluridine did have some antitumor activity in early-
phase trials, further development of single-agent trifluridine
was discontinued because its suboptimal pharmacokinetics
(PK) required dosing schedules that were infeasible [5, 6].
The development of a potent and specific chemical inhibitor
of thymidine phosphorylase, tipiracil hydrochloride, created an
opportunity to improve the PK properties of trifluridine [3]. The
coadministration of oral trifluridine and tipiracil in mice and
monkeys led to an increased bioavailability of trifluridine
[3, 7]. Compared with trifluridine alone, the oral coadministra-
tion of trifluridine and tipiracil led to a marked increase in the
trifluridine area under the concentration–time curve (AUC) and
maximum observed plasma concentration (Cmax) [3].
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Trifluridine/tipiracil (TAS-102) is a new orally active anti-
neoplastic agent comprised of trifluridine and tipiracil in a
molar ratio of 1:0.5. In Japanese phase 1 and 2 studies in solid
tumors, trifluridine/tipiracil was well tolerated, with the pri-
mary toxicity being myelosuppression [8–11]. The global
phase 3 RECOURSE trial demonstrated that trifluridine/
tipiracil is efficacious in refractory metastatic colorectal can-
cer. The RECOURSE trial showed that, compared with a pla-
cebo control, trifluridine/tipiracil increased overall survival in
patients with refractory metastatic colorectal cancer by
1.8 months [12]. The results of the RECOURSE trial led the
US Food and Drug Administration (FDA) to approve
trifluridine/tipiracil for patients with refractory metastatic
colorectal cancer.
The objective of the current study was to demonstrate the
ability of tipiracil, when administered in combination with
trifluridine as trifluridine/tipiracil, to increase the exposure to
trifluridine in patients with advanced solid tumors. Exposure
to trifluridine was compared after administration of equivalent
trifluridine doses either in the presence of tipiracil (as




This was a phase 1, open-label, randomised, parallel, two-
group study conducted in four centers in the United States
from May 2013 to January 2014. The study was carried out
in two stages (single-dose and multiple-dose) using a 28-day
treatment cycle (Fig. 1).
Study population
Men and women aged 18 years or older, with histologically or
cytologically confirmed advanced solid tumors for which no
standard therapy existed, were selected for study. This study
was conducted in accordance with the ethical principles in the
Declaration of Helsinki (2008), the US Code of Federal
Regulations (Title 21, 312.50 through 312.70), the
International Council for Harmonisation Tripartite Guidelines
for Good Clinical Practice, and local and national laws and
regulations governing the use of investigational therapeutic
agents. The study protocol and other relevant documents re-
ceived approval from the Institutional Review Board/
Independent Ethics Committee prior to patient enrollment.
Written informed consent was obtained from each patient.
The study is registered on ClinicalTrials.gov: NCT01867866.
Patients were required to have Eastern Cooperative
Oncology Group (ECOG) performance status 0 or 1 on day
1 of cycle 1 as well as being able to take medications orally.
The eligibility criteria also required a serum creatinine
≤1.5 mg/dL, serum bilirubin ≤1.5 × the upper limit of normal
(ULN), and adequate function of the bone marrow (absolute
neutrophil count ≥1500/μL; platelets ≥100,000/mm3; hemo-
globin ≥9.0 g/dL).
Major exclusion criteria included treatment with anticancer
therapy within the prior 3 weeks (mitomycin within the prior
5 weeks), investigational agent received either concurrently or
within the last 30 days or five half-lives (whichever was
shorter), current enrolment in another interventional clinical
study, serious illness or medical condition, and unresolved
toxicity of National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI CTCAE) Grade ≥ 2 attrib-
uted to prior therapies.
Treatment
Patients were stratified into two groups according to body
surface area (<1.8 m2; ≥1.8 m2) and randomized to receive a
single dose of trifluridine/tipiracil (group 1) or trifluridine
alone (group 2).
Single dose
The single-dose stage of the study was conducted on the
morning of day 1 of cycle 1. After an overnight fast of at least
8 h and within 30 min after completion of a standardized,
high-fat, high-calorie breakfast, a dose of trifluridine/tipiracil
(trifluridine:tipiracil molar and weight ratios of 1:0.5 and
1:0.471, respectively) or trifluridine alone was administered.
On the morning of day 1, cycle 1, patients in group 1 received
a single oral dose of trifluridine/tipiracil 35 mg/m2, while pa-
tients in group 2 received a single oral dose of
trifluridine 35 mg/m2. Blood samples were collected
from all patients on day 1 at the following times: 0 (predose)
and 15 min, 30 min, 1 h, 1 h 30 min, 2, 3, 4, 6, 8, 10, and 12 h
postdose.
Multiple dose
All patients (from groups 1 and 2 of the single-dose stage)
received trifluridine/tipiracil in the multiple-dose stage. The
multiple-dose stage of the study began with the evening dose
of trifluridine/tipiracil on day 1 of cycle 1 after collection of
the 12-h postdose PK blood sample in the single-dose stage.
Trifluridine/tipiracil 35 mg/m2/dose was then administered
orally twice daily on days 2–5 of cycle 1, with doses admin-
istered within 1 h after completion of the morning (AM dose)
and evening (PM dose) meals. This was followed by a recovery
period from day 6 to day 7. Trifluridine/tipiracil was again
administered orally twice daily on days 8–12, with the last
dose administered in the evening of day 12. Blood samples
were collected on day 12 of cycle 1 at the following times: 0
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(AM predose) and 30min, 1, 2, 4, 8, and 12 h postdose. Day 12
was followed by a recovery period from day 13 to day 28.
All patients continued to receive the 28-day cycle of
trifluridine/tipiracil 35 mg/m2 until disease progression, intol-
erable toxicity, or need for more than three dose reductions of
trifluridine/tipiracil due to an unacceptable adverse event
(AE). Blood samples were collected on day 12 of cycles 2
and 3 at the following times: 0 (AM predose), and 30 min, 1,
2, 4, 8, and 12 h postdose. Efficacy and safety assessments
were performed during the multiple-dose stage of the study.
Evaluation parameters
To assess treatment compliance, the number of tablets dis-
pensed and returned by the patient was recorded for each
treatment cycle. Any dose reductions or interruptions were
recorded along with the reasons for those actions.
Pharmacokinetics
PK parameters for trifluridine, FTY, and tipiracil in plasma
following administration of a single dose of trifluridine/
tipiracil or trifluridine alone were determined using standard,
noncompartmental methods. The primary endpoints for com-
parison of trifluridine/tipiracil and trifluridine alone (single-
dose) were AUC from hour 0 to the time of last measurable
plasma concentration (AUC0-last) (after the morning dose) for
trifluridine estimated by the linear trapezoidal rule and Cmax of
trifluridine after the morning dose.
The secondary endpoints for single-dose administration
were PK parameters for trifluridine, FTY, and tipiracil, includ-
ing AUC from time zero to infinity (AUC0-inf), time of max-
imum observed plasma concentration (Tmax), and terminal
half-life (T½). Secondary endpoints for multiple-dose admin-
istration were PK parameters for trifluridine, FTY, and
tipiracil. AUC0-last, Cmax, Tmax, and T½ for those compounds
and were determined on day 12 of cycles 1, 2, and 3.
Efficacy
For patients whowere continuing to receive treatment at the time
of the data cutoff, data were collected for all completed cycles
prior to and including the cutoff date. Tumor assessments were
performed throughout the study based on review of computed
tomography (CT) scans and following Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1, 2009. CT scans
of the chest, abdomen, and pelvis (as clinically indicated) were
performed at the end of every 8 weeks through cycle 6. After
cycle 6, the follow-up tumor assessment schedule could be ad-
justed to conform to the site standard of care, provided that
follow-up scans were performed at least every 12 weeks.
Disease control was defined as having complete response, partial
response, or stable disease. For a patient to be categorized as
having Bstable disease,^ the patient had to maintain stable dis-
ease for at least 6 weeks from the start of treatment.
Safety
Standard safety monitoring and grading were performed using
NCI CTCAE version 4.03. The evaluation of safety was based
on the incidence, severity, and causality of adverse events
(AEs) and serious AEs and other safety assessments, includ-
ing physical examination, vital signs, ECOG performance sta-
tus, 12-lead electrocardiogram, and clinical laboratory evalu-
ations. Safety data were summarized descriptively.
Statistical methods
Sample size
The investigators who designed this study planned to enroll
approximately 40 patients. Assuming an attrition rate of 20%
for dropouts and patients for whomPK data were not available
or able to be evaluated, a total of 20 patients per treatment
group were to be enrolled in the single-dose stage to ensure
that at least 16 patients in each group completed this stage of
the study. This would provide 80% power to detect a 1.67-fold
change (ratio of the geometric means of AUCs for trifluridine
as trifluridine/tipiracil and trifluridine alone), that is, a 67%
increase in the trifluridine/tipiracil arm. This calculation was
based on a two-group t-test, assuming a log-normal distribu-
tion, a coefficient of variation (CV) of 50%, one interim anal-
ysis, and a two-sided overall study alpha of 5%.
No prior clinical information existed for the expected in-
crease in trifluridine AUC with trifluridine/tipiracil relative to
trifluridine alone. The targeted effect of 67% was chosen so
that the minimum detectable difference was at least as large as
the inherent variability in trifluridine AUC (CV of 50%). At
Fig. 1 Study design. PK,
pharmacokinetics
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least six patients with evaluable multiple-dose PK profiles for
all three cycles and no dose reductions for the first three cycles
of treatment in the multiple-dose stage were required to satisfy
the additional study objective to investigate multiple-dose PK
of trifluridine/tipiracil.
Pharmacokinetics
The PK parameters were compared for trifluridine/tipiracil
and trifluridine alone using a t-test based on the log-
transformed PK parameters. Ninety-five percent CIs were de-
rived for the differences in the log-transformed means. Point
estimates and confidence limits were exponentiated after the
analysis and presented as ratios. PK parameters for
trifluridine, FTY, and tipiracil in plasma following administra-
tion of multiple doses of trifluridine/tipiracil (day 12 of cycles
1, 2, and 3) were summarized descriptively.
Results
Patient disposition
A total of 44 patients were enrolled, randomized, and treated,
with 22 patients in the single-dose group of trifluridine/
tipiracil (group 1) and 22 patients in the single-dose group of
trifluridine (group 2). Of the patients who participated in the
single-dose stage of the study, 39 (88.6%) were evaluable.
Three patients in group 1 were excluded for the following
reasons: incorrect dose, significant inclusion criteria violation,
and fasting conditions not met (one patient each). Two patients
in group 2 were excluded due to an error in collecting blood
samples or missing samples/assays (one patient each). A total
of 39 patients were evaluable as a single-dose PK population,
with 19 patients in the trifluridine/tipiracil group and 20 pa-
tients in the trifluridine alone group.
Demographic and baseline characteristics were similar for
patients in group 1 and group 2 in the single-dose PK popu-
lation (Table 1) as well as in the safety population. The study
population consisted of 22 men and 22 women with a mean
age of 57.0 years; 90.9% were white and 75% had an ECOG
performance status of 1. The majority (61.4%) of patients had
colon cancer; 68.2% had received ≥4 prior chemotherapy reg-
imens, indicating that they were heavily pretreated.
Following the initial morning dose on day 1, all patients in
both groups (n = 44) went on to the multiple-dose stage of the
study. Six patients who received at least one cycle of treatment
were excluded from the analysis due to missing PK data (six
patients) and/or dosing deviation (two patients). A total of 38
patients were evaluable for PK analysis for at least one cycle; of
these, nine patients were evaluable for PK analysis at cycle 3.
The remainder of the patients discontinued treatment or had a
dose reduction prior to the completion of cycle 3 PK assessment.
As of the data cutoff date (January 21, 2014), 36 (81.8%)
patients had discontinued study treatment. The most frequent
reason for discontinuing treatment was radiographic evidence
of disease progression (36.4%), with clinical disease progres-
sion (20.5%) being the second most frequent cause. Patient
cancer types included colon (61.4%), pancreas (11.4%), rectal




Administration of trifluridine/tipiracil resulted in a significant
increase in exposure to trifluridine compared with administra-
tion of trifluridine alone (Fig. 2). Based on the ratio of the
geometric mean estimates, trifluridine AUC0-last was approx-
imately 37-fold higher following administration of
trifluridine/tipiracil than following administration of
trifluridine alone (Table 2). In addition, trifluridine Cmax was
approximately 22-fold higher and trifluridine AUC0-inf was
27-fold higher for trifluridine/tipiracil compared with
trifluridine alone (Table 2).
As expected, plasma concentrations of FTY (inactive me-
tabolite) were lower following administration of trifluridine/
tipiracil compared with trifluridine alone due to extensive me-
tabolism of trifluridine when administered alone. The ratio of
the geometric mean estimates was less than 1 for AUC0-last
(0.78), Cmax (0.67), and AUC0-inf (0.79) (Table 2).
The mean and geometric mean Cmax values for trifluridine
after administration of trifluridine alone were lower (138 and
96 ng/mL, respectively) than after administration of
trifluridine/tipiracil (2381 and 2155 ng/mL, respectively)
(Tables 2 and 3). For trifluridine Cmax calculations, the CV
was higher after administration of trifluridine alone than
after administration of trifluridine/tipiracil (92% vs 44%,
respectively) (Table 3). The lower and more variable
plasma concentrations of trifluridine are consistent with
the poor bioavailability of trifluridine after oral administration
of trifluridine alone.
In comparing trifluridine/tipiracil with trifluridine alone ad-
ministration, trifluridine/tipiracil had a higher trifluridine geo-
metric mean AUC0-last (6618 vs 176 ng•h/mL, respectively),
similar trifluridine median Tmax (1.50 vs 1.50 h, respectively),
and similar trifluridine mean T½ time (1.42 vs 1.14 h, respec-
tively) (Tables 2 and 3). This suggests that bioavailability was
the primary difference between trifluridine/tipiracil and
trifluridine alone.
Multiple dose
Descriptive statistics for trifluridine plasma PK parameters
following single- and multiple-dose trifluridine/tipiracil
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administration show that the mean trifluridine AUC0-last was
approximately 3-fold higher than after single-dose trifluridine/
tipiracil administration (n = 19) and that mean Cmax was ap-
proximately 2-fold higher. The AUC0-last for FTY was also
increased after multiple dosing of trifluridine/tipiracil
compared with a single dose; however, Cmax values for
FTY were similar after single and multiple dosing. For
tipiracil, AUC0-last and Cmax were similar after single-
and multiple-dose administration of trifluridine/tipiracil
(Table 3).
Safety
Dose reductions and delays
Across all cycles, 17 of 44 (38.6%) patients received
concomitant granulocyte colony-stimulating factor and
39 of 44 (88.6%) patients received ≥80% of their target
cycle dose.
Thirty-eight of 44 (86.4%) patients maintained the
starting dose of 35 mg/m2 twice daily throughout their
participation in the study. Six (13.6%) patients had a
single dose reduction to 30 mg/m2 twice daily at the
start of cycle 2 or 3. For these six patients, dose reductions
were due to neutropenia (four patients), febrile neutro-
penia (one patient), and anemia (one patient). Of the 36
patients who initiated at least two cycles of treatment,
eight (22.2%) experienced at least one cycle initiation
delay of ≥8 days. Eight of all 61 (13.1%) cycles admin-
istered were delayed by ≥8 days. Of the eight patients
with a delay of ≥8 days in cycle initiation, the reasons were
Grade 3/4 neutropenia (five patients), Grade 2 neutrope-
nia (two patients), and Grade 4 febrile neutropenia (one
patient). As of the data cutoff date of the extension
stage of the study, 44 patients had initiated at least
one cycle of trifluridine/tipiracil treatment. The mean num-
ber of cycles initiated was 2.4 and the mean number of weeks
followed was 7.7 (range 1–6).
Table 1 Demographic and baseline characteristics, single-dose stage







Mean age (± SD), y 56.2 (11.69) 57.5 (7.58) 56.9 (9.69) 57.0 (10.04)
Gender, n (%)
Male 10 (52.6) 11 (55.0) 21 (53.8) 22 (50.0)
Female 9 (47.4) 9 (45.0) 18 (46.2) 22 (50.0)
Race, n (%)
White 17 (89.5) 19 (95.0) 36 (92.3) 40 (90.9)
Black/African heritage 1 (5.3) 1 (5.0) 2 (5.1) 3 (6.8)
Asian 1 (5.3) 0 1 (2.6) 1 (2.3)
Mean weight (± SD)a, kg 81.8 (18.07) 73.7 (15.54) 77.7 (17.09) 77.3 (17.88)
BSA, mean (± SD), m2 1.95 (0.244) 1.82 (0.214) 1.88 (0.234) 1.88 (0.246)
Stratification BSAa, n (%)
< 1.8 m2 5 (26.3) 8 (40.0) 13 (33.3) 16 (36.4)
≥ 1.8 m2 14 (73.7) 12 (60.0) 26 (66.7) 28 (63.6)
ECOG performance status, n (%)
0 6 (31.6) 3 (15.0) 9 (23.1) 11 (25.0)
1 13 (68.4) 17 (85.0) 30 (76.9) 33 (75.0)
Prior radiotherapy, n (%)
Yes 6 (31.6) 12 (60.0) 18 (46.2) 20 (45.5)
No 13 (68.4) 8 (40.0) 21 (53.8) 24 (54.5)
Number of regimensb, n (%)
1–2 3 (15.8) 6 (30.0) 9 (23.1) 10 (22.7)
3 3 (15.8) 1 (5.0) 4 (10.2) 4 (9.1)
≥ 4 13 (68.4) 13 (65.0) 26 (66.7) 30 (68.2)
BSA body surface area, ECOG Eastern Cooperative Oncology Group, PK pharmacokinetics, SD standard deviation
a Per Interactive Web Response System (height and weight collected at baseline)
b Includes all prior systemic therapies (neoadjuvant, adjuvant, metastatic)
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AEs were reported for 43 of 44 patients treated; most pa-
tients (88.6%) had AEs that were considered treatment-relat-
ed. The most frequently reported treatment-related AEs were
nausea (47.7%), fatigue (31.8%), anemia (27.3%), decreased
neutrophil count (25.0%), diarrhea (22.7%), vomiting
(22.7%), and decreased white blood cell count (18.2%). The
most common Grade ≥ 3 treatment-related AEs (reported for
≥10% of patients) were anemia (18.2%), neutropenia (13.6%),
and leukopenia (13.6%). Five patients died as of the cutoff
date; three deaths were attributed to clinical disease progres-
sion, one to radiologic disease progression, and one to upper
gastrointestinal haemorrhage and hemorrhagic shock, which
was not considered treatment-related. Six patients experienced
a serious AE, which was considered treatment-related, the
most frequent of which were cytopenias. Two patients expe-
rienced serious AEs classified as decreased appetite and
dehydration.
Efficacy
At the time of data cutoff, there were no partial or complete
responses observed; 23 patients had stable disease for
≥6 weeks (according to standard RECIST criteria), and 18
patients had progressive disease. The rate of disease control
was 52%.
Discussion
Previous efforts to develop trifluridine as a therapeutic agent
were hampered by its poor bioavailability, which is due to its
rapid degradation via thymidine phosphorylase. The develop-
ment of the thymidine phosphorylase inhibitor, tipiracil, cre-
ated an opportunity to utilize trifluridine in the clinic. TAS-
102, a combination tablet of trifluridine and tipiracil, was de-
veloped based on the hypothesis that inhibition of thymidine
phosphorylase would increase the bioavailability of
trifluridine. The results of this randomized PK study are proof
of concept that inhibition of thymidine phosphorylase with
tipiracil leads to a substantially increased exposure to
trifluridine. Compared with trifluridine alone, the combination
of tipiracil and trifluridine resulted in a 37-fold increase in
AUC0-las t and 22-fold increase in Cmax (Table 2).
Importantly, these results demonstrate the pharmacologic fea-
sibility of utilizing an oral combination of trifluridine and
tipiracil. This is further supported by the placebo-controlled,
phase 3 RECOURSE trial, which found that trifluridine/
Table 2 Single-dose PK of trifluridine/tipiracil and trifluridine
Parameter Trifluridine/tipiracil Trifluridine Ratio of Geometric Mean
([Trifluridine/tipiracil]/Trifluridine)
N Geometric Mean N Geometric Mean Estimate 95% CI
Trifluridine
AUC0-last (ng•h/mL) 19 6618 20 176 37.55 27.56–51.15
Cmax (ng/mL) 19 2155 20 96 22.39 14.19–35.34
AUC0-inf (ng•h/mL) 19 6694 10
a 248 27.00 19.56–37.27
FTY
AUC0-last (ng•h/mL) 19 3232 20 4122 0.78 0.65–0.94
Cmax (ng/mL) 19 737 20 1104 0.67 0.54–0.82
AUC0-inf (ng•h/mL) 19 3320 20 4179 0.79 0.66–0.96
AUC0-last area under the curve from hour 0 to the last measurable plasma concentration, AUC0-inf area under the curve from hour 0 to infinity, Cmax
maximum observed plasma concentration, FTY 5-trifluoromethyluracil, PK pharmacokinetics
a Due to low and fluctuating plasma trifluridine concentrations after administration of trifluridine alone, AUC0-inf could only be deter-



































Fig. 2 Single-dose PK studies. For this analysis, patients received either a
single oral dose of trifluridine/tipiracil at 35 mg/m2 (dose rounded to the
nearest 5 mg) or a single oral dose of trifluridine at 35 mg/m2. Blood
samples were collected from all patients at the following times: 0
(predose) and 15 min, 30 min, 1 h, 1 h 30 min, 2, 3, 4, 6, 8, 10, and 12 h
postdose. FTD, trifluridine; PK, pharmacokinetic; TPI, tipiracil
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Multiple Dose (≥1 cycle)
Cycle 1,
Day 1 (N = 19)
Cycle 1,
Day 1 (N = 20)
Cycle 1,
Day 12 (N = 34)
Cycle 2,
Day 12 (N = 25)
Cycle 3,
Day 12 (N = 9)
Trifluridine
AUC0-last (ng•h/mL)
Mean 7045 200 23,697 25,056 26,696
SD 2411 96 7419 10,586 9219
CV 34% 48% 31% 42% 35%
Cmax (ng/mL)
Mean 2381 138 4857 5458 5297
SD 1048 127 1930 2269 2291
CV 44% 92% 40% 42% 43%
Tmax (h)
Median 1.50 1.50 1.97 2.00 2.00
Min, Max 0.53, 4.00 0.25, 6.00 0.50, 8.00 0.50, 4.00 1.00, 4.00
T1/2 (h)
Na 19 10 26 19 5
Mean 1.42 1.14 2.07 2.10 2.55
SD 0.42 0.55 0.43 0.50 0.79
CV 30% 48% 21% 24% 31%
FTY
AUC0-last (ng•h/mL)
Mean 3344 4281 5206 5736 5832
SD 897 1132 2055 2345 1938
CV 27% 26% 39% 41% 33%
Cmax (ng/mL)
Mean 765 1169 679 754 783
SD 201 402 200 205 220
CV 26% 34% 29% 27% 28%
Tmax (h)
Median 3.00 2.00 2.00 2.00 3.93
Min, Max 1.00, 6.08 0.30, 6.00 0.50, 8.00 1.00, 8.00 1.03, 4.00
T1/2 (h)
Na 19 20 9 6 0
Mean 1.76 1.28 4.51 3.76 NA
SD 0.38 0.33 0.53 0.59 NA
CV 21% 26% 12% 16% NA
Tipiracil
AUC0-last (ng•h/mL)
Mean 301 – 372 333 299
SD 127 – 135 124 92
CV 42% – 36% 37% 31%
Cmax (ng/mL)
Mean 69 – 69 66 54
SD 30 – 27 25 17
CV 43% – 40% 39% 32%
Tmax (h)
Median 3.00 – 2.01 3.25 4.00
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tipiracil improved survival in patients with refractory colorec-
tal cancer [12].
Preclinical pharmacology studies similarly found that oral
coadministration of trifluridine and tipiracil markedly in-
creases the Cmax and AUC of trifluridine. In monkeys, the oral
coadministration of equimolar trifluridine and tipiracil led to a
70-fold increase in Cmax and approximately a 100-fold in-
crease in AUC [3]. The results obtained in the present clinical
study were similar to those observed in the preclinical studies
on monkeys. Furthermore, the results of this study demon-
strate the poor bioavailability of trifluridine when adminis-
tered alone, which is also consistent with the results of previ-
ous preclinical and clinical trials performed on trifluridine [5].
As shown in Tables 2 and 3, the Cmax of trifluridine after
administration of trifluridine alone was significantly lower
than that after trifluridine/tipiracil (96 ng/mL for trifluridine
alone vs 2155 ng/mL for trifluridine/tipiracil). In addi-
tion to trifluridine alone having poor bioavailability, it
also had more variable plasma concentrations of
trifluridine. Single-agent trifluridine’s Cmax CV (CV = 92%;
range: 25–504 ng/mL) was approximately double that ob-
served after the administration of trifluridine/tipiracil
(CV = 44%; range: 979–4190 ng/mL). The lower and more
variable plasma concentrations of trifluridine when given
alone confirmed that trifluridine cannot be effectively admin-
istered orally as an anticancer therapywithout being combined
with tipiracil (Fig. 2).
The 3-fold higher mean trifluridine AUC0-last after multiple
doses of trifluridine/tipiracil is consistent with a previous
study in Japanese patients, in which the accumulation ratio
for trifluridine AUC was 2.4 (at the same dosage and dosing
regimen) (Table 3) [10]. Although the mechanism has not
been identified, the accumulation of trifluridine after repeated
administration does not appear to be a safety or efficacy risk of
trifluridine/tipiracil because the accumulation of trifluridine
AUC is not dose-dependent [10]. Furthermore, the variability
for the accumulation ratio of trifluridine is relatively small, as
it ranged from 2- to 4.5-fold (Table 3). Multiple-dose PK
analyses show that accumulation of trifluridine is limited to
the first 28-day treatment cycle, with no further accumulation
over subsequent cycles, up to cycle 3 in this study. Similar
results were observed for FTY and tipiracil.
In this study, which utilized the same dosage regimen as in
the RECOURSE trial, trifluridine/tipiracil was found to be
generally well tolerated in heavily pretreated patients
with solid tumors. Similar to the safety results of the
RECOURSE trial, the major toxicity in this study was
myelosuppression. In terms of antitumor efficacy, no objective
responses to trifluridine/tipiracil were observed in this trial,
which is consistent with the observations of the
RECOURSE trial. While trifluridine/tipiracil treatment led to
a 1.8-month improvement in survival compared with placebo,
the RECOURSE trial demonstrated that the response rate to
trifluridine/tipiracil in patients with refractory metastatic colo-
rectal cancer was only 1.6%. In RECOURSE, disease control
was achieved in 44% patients in the trifluridine/tipiracil group
compared to 16% patients in the placebo group [12].
Consistent with this, disease control was observed in 52% of
patients in our trial.
In conclusion, exposure to trifluridine is significantly in-
creased when it is administered in combination with tipiracil.
This demonstrates the essential contribution of tipiracil and
the rationale for its combination with trifluridine in the form
of trifluridine/tipiracil. Similar to the observations in other
trials, trifluridine/tipiracil was well tolerated in this
study and the major toxicity was myelosuppression.
Trifluridine/tipiracil is now approved in Japan, Europe,
and the United States for patients with refractory metastatic








Multiple Dose (≥1 cycle)
Cycle 1,
Day 1 (N = 19)
Cycle 1,
Day 1 (N = 20)
Cycle 1,
Day 12 (N = 34)
Cycle 2,
Day 12 (N = 25)
Cycle 3,
Day 12 (N = 9)
Min, Max 1.02, 8.00 – 1.00, 8.03 1.00, 8.00 1.97, 4.08
T1/2 (h)
a
Na 16 – 19 12 2
Mean 2.10 – 2.40 2.51 2.31
SD 0.47 – 0.59 0.69 1.03
CV 22% – 24% 27% 44%
AUC0-last area under the curve from hour 0 to the last measurable plasma concentration, Cmax maximum observed plasma concentration, CV coefficient
of variation, FTY 5-trifluoromethyluracil, NA not available,Max maximum,Min minimum, PK pharmacokinetics, SD standard deviation, T1/2 terminal
half-life, Tmax time of maximum observed plasma concentration
a Due to fewer sampling time points on day 12 (30 min, 1, 2, 4, 8, and 12 h postdose), half-life could not be calculated for some patients
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